Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP26A1 | O43174 | 7/20 | 0.53 |
| ▸ | FDPS | P14324 | 1/20 | 0.46 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.44 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
| ▸ | RAB9A | P51151 | 1/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL21879108 | 0.98 | CYP26A1 (0.52) | CYP26A1FDPSCYP3A4CYP2D6ALDH1A1 | |
| SCHEMBL18167013 | 0.82 | CYP26A1 (0.51) | CYP26A1FDPSALDH1A1RAB9AKDM4E | |
| SCHEMBL29852327 | 0.82 | CYP26A1 (0.51) | CYP26A1FDPSALDH1A1RAB9AKDM4E | |
| SCHEMBL29852757 | 0.82 | CYP26A1 (0.51) | CYP26A1FDPSALDH1A1RAB9AKDM4E | |
| Hydrochloric Acid SCHEMBL27568543 | 0.81 | CYP26A1 (0.50) | CYP26A1FDPSCYP3A4CYP2D6ALDH1A1 | |
| SCHEMBL5324131 | 0.80 | ALDH1A1 (0.53) | FDPSALDH1A1KDM4E | |
| SCHEMBL8241715 | 0.80 | ALDH1A1 (0.53) | FDPSALDH1A1KDM4E | |
| SCHEMBL12243286 | 0.78 | ALDH1A1 (0.38) | CYP26A1ALDH1A1KDM4E | |
| SCHEMBL16328527 | 0.77 | QPCT (0.49) | CYP26A1FDPSALDH1A1 | |
| SCHEMBL28723149 | 0.75 | ALDH1A1 (0.49) | CYP26A1FDPSALDH1A1RAB9AKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11345669-B2 | Urea derivatives and methods of use thereof | NodThera Limited (GB) | 2022-05-31 | — | — | US | disclosed |
| US-20200131141-A1 | CHEMICAL COMPOUNDS | NodThera Limited (GB) | 2020-04-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200131141-A1 | CHEMICAL COMPOUNDS | IL1B, CASP1, IL1A | CYP26A1 1632/4885FDPS 232/4885CYP3A4 2266/4885 |
| US-11345669-B2 | Urea derivatives and methods of use thereof | IL1B, IL1A, NOD1 | CYP26A1 1462/4885FDPS 578/4885CYP3A4 1741/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.